<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179127</url>
  </required_header>
  <id_info>
    <org_study_id>040643</org_study_id>
    <nct_id>NCT00179127</nct_id>
  </id_info>
  <brief_title>Use of Insulin Glargine to Treat Diabetic Ketoacidosis</brief_title>
  <official_title>Early Use of Insulin Glargine in Diabetic Ketoacidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of the addition of insulin glargine
      during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children.

      The investigators hypothesize that the addition of insulin glargine during the early phase of
      management of DKA will accelerate acidosis correction, decrease the length of insulin
      infusion, and decrease the total intensive care unit time in children admitted to the ICU.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2004</start_date>
  <completion_date type="Anticipated">September 2012</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of acidosis correction</measure>
    <time_frame>Minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time on insulin drip</measure>
    <time_frame>Minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospital stay</measure>
    <time_frame>Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Diabetic Ketoacidosis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glargine</intervention_name>
    <description>0.3u/kg of glargine, subq, once</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>0.3cc/kg of saline, subq, once</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 6-18 y.o. presenting to VCH E.R. with:

          -  Established history of insulin dependent diabetes

        AND:

          -  Chief c/o hyperglycemia or vomiting

          -  Venous pH &lt; 7.24

          -  Serum Bicarbonate &lt; 18

          -  Blood glucose &gt; 150

          -  Urinary Ketones

        Exclusion Criteria:

          -  Age &lt; 6y.o.

          -  New onset diabetes

          -  Received IV insulin bolus prior to arrival to VCH E.R.

          -  Venous pH &gt; 7.24

          -  Serum Bicarbonate &gt; 18

          -  Pregnancy

          -  Received glargine within 12 hours prior to arrival to VCH E.R./PCCU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila McMorrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Monroe Carell Children's Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>June 20, 2012</last_update_submitted>
  <last_update_submitted_qc>June 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Sheila McMorrow</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Emergency Care</keyword>
  <keyword>Endocrinology</keyword>
  <keyword>Critical Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 2, 2018</submitted>
    <returned>May 8, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

